Chargement de l’entreprise
Just reported
Q3 2026 results
From Myriad Genetics's results release of 4 novembre 2026; its quarterly report has since been filed.
Revenue
Actual
202,7M $US
-1,5 % y/y
+6,3 % q/qGuided
—
No guide given
EPS, GAAP
Actual
-0,46 $US
Guided
—
No guide given
Operating income, GAAP
Actual
-39,9M $US
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Keep exploring
The themes Myriad Genetics is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Diagnostics and Research
Graded A or B and worth $2B or more: A first, then the largest.
TMOThermo Fisher Scientific Inc.259,4B $USA+
IDXXIdexx Laboratories Inc.55,5B $USA+
IQVIQVIA Holdings Inc.43,7B $USA
ILMNIllumina, Inc.31,3B $USA+
LHLabcorp Holdings Inc.30,1B $USA
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 oct. 2026CBGraded C, now B
MCKMckesson Corporation4 nov. 2026BAGraded B, now A
CVSCVS Health Corp4 nov. 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 nov. 2026BAGraded B, now A
GEHCGE Healthcare Technologies Inc.28 oct. 2026CAGraded C, now A
Construit à partir des documents déposés par Myriad Genetics, Inc. auprès de la Securities and Exchange Commission (SEC), le gendarme boursier américain. Les chiffres sont tels que publiés, l’historique par action étant retraité sur la base d’actions d’aujourd’hui. Ceci décrit une entreprise — ce n’est pas un conseil en investissement ni une recommandation d’acheter ou de vendre.
